Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start : Episode 4

Opinion

Video

May 24, 2024

HIV Treatment: Discussing Adverse Events with Patients

Author(s):

Paul E. Sax, MD,Shauna Applin, ARNP

Experts on the treatment of HIV discuss how they talk with their patients about adverse effects associated with HIV regimens.

EP: 1.The Role of the Primary Care Provider/Advanced Practice Provider in HIV Management

EP: 2.Evolving Treatment Practices and Guidelines for HIV

EP: 3.Key Clinical Considerations in HIV Treatment Decisions

EP: 4.HIV Treatment: Discussing Adverse Events with Patients

EP: 5.Importance of Starting HIV Treatment Early

EP: 6.Treatment Resistance in HIV

EP: 7.HIV Drug Resistance Testing Practices and Patient Education

EP: 8.Managing Suboptimal Adherence to HIV Medications

EP: 9.HIV Treatment Clinical Experiences

EP: 10.Addressing Suboptimal Treatment Response in HIV

EP: 11.Current HIV Treatment Regimens

EP: 12.Rapid Treatment Initiation in HIV

EP: 13.Switching Therapies for Patients with HIV and History of Resistance

EP: 14.Resources Available for Patients with HIV Drug Resistance

EP: 15.Factors that Inform Treatment Selection in HIV

EP: 16.Switching Therapies in HIV

EP: 17.Restarting Therapy in Patients with HIV

EP: 18.Treatment Guidelines and Regimens for Managing Patients with HIV

EP: 19.Differences in Binding Affinity Between Integrase Inhibitors in HIV

EP: 20.Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens

EP: 21.Recent Studies on HIV Treatments and Patient-Reported Outcomes

EP: 22.HIV: Treating Patients with Viral Mutations

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question:

1. What are the key clinical considerations for choosing between the integrase strand transfer inhibitors (NSTIs) for treatment naïve patient with HIV?

Related Videos

Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD

Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center

Investigating Brensocatib, Potential First Treatment for Bronchiectasis, with James Chalmers, MBChB, PhD

Aflibercept 8 mg Noninferior for RVO in QUASAR with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center

AI in Dermatology: Emerging Insights and Diverging Perspectives

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.